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SR9009 administered for one day after myocardial
ischemia-reperfusion prevents heart failure in mice
by targeting the cardiac inﬂammasome
Cristine J. Reitz1, Faisal J. Alibhai1, Tarak N. Khatua1, Mina Rasouli1, Byram W. Bridle2, Thomas P. Burris3 &
Tami A. Martino 1*

Reperfusion of patients after myocardial infarction (heart attack) triggers cardiac
inﬂammation that leads to infarct expansion and heart failure (HF). We previously showed
that the circadian mechanism is a critical regulator of reperfusion injury. However, whether
pharmacological targeting using circadian medicine limits reperfusion injury and protects
against HF is unknown. Here, we show that short-term targeting of the circadian driver
REV-ERB with SR9009 beneﬁts long-term cardiac repair post-myocardial ischemia reperfusion in mice. Gain and loss of function studies demonstrate speciﬁcity of targeting REV-ERB in
mice. Treatment for just one day abates the cardiac NLRP3 inﬂammasome, decreasing
immunocyte recruitment, and thereby allowing the vulnerable infarct to heal. Therapy is given
in vivo, after reperfusion, and promotes efﬁcient repair. This study presents downregulation
of the cardiac inﬂammasome in ﬁbroblasts as a cellular target of SR9009, inviting more
targeted therapeutic investigations in the future.
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I

schemic heart disease leading to myocardial infarction (MI,
heart attack) is a leading cause of morbidity and mortality1.
Although many patients reach hospitals in a timely manner
and undergo post-ischemia reperfusion (mI/R), unfortunately this
triggers a profound inﬂammatory response termed “reperfusion
injury”, which in turn leads to infarct expansion and adverse
cardiac remodeling and pathological progression to heart failure
(HF) for which there is no cure2–5. Although we cannot predict
when an individual will experience an MI, we can devise strategies
to reduce reperfusion injury after MI, thereby reducing deleterious remodeling to improve on quality of life and outcomes. Here,
we demonstrate how targeting the circadian mechanism reduces
the NLRP3 inﬂammasome, leading to less reperfusion injury.
Treatment for as little as 1 day post-mI/R provides a window of
time in which the infarct region can intrinsically heal, thereby
reducing adverse remodeling and protecting against the development of HF.
The basis for our approach is built on the solid existing
foundation of clinical and experimental evidence showing that the
immune system plays a fundamental role in mitigating reperfusion injury post-mI/R6–10. It has long been thought that reducing
the early inﬂammatory responses is a key promising strategy for
intervention4,9,11. However, earlier studies targeting the immune
system used broad approaches that failed to show clinical effectiveness, likely in large part because they mitigated not only the
deleterious pathways involved in infarct healing but also the
beneﬁcial pathways that were crucial for healing12. Our innovative approach is based on speciﬁc targeting of the circadian
mechanism, which we recently discovered is a key regulator of
immunocyte recruitment to infarcted myocardium10. Here, we
show that targeting the circadian mechanism at the time of
reperfusion limits formation of the cardiac NLRP3 inﬂammasome
to reduce the subsequent cascade of inﬂammatory responses that
are involved in infarct expansion, with clear beneﬁts on cardiac
structure, function, and outcome.
Circadian medicine to beneﬁt treatment of clinically relevant
mI/R has never been pursued, because to date we lacked the
pharmacology to do so. However, most recently we have developed pharmacology that targets the circadian mechanism, such as
the core driver REV-ERB. In this study, we target REV-ERB postmI/R to increase the constitutive repression of genes regulated by
REV-ERB13, including the inﬂammasome that drives adverse
immune recruitment to the infarcted myocardium. We use the
clinically relevant murine coronary artery ligation/reperfusion
mI/R model, and the REV-ERB agonist SR900913, to simulate the
possible effects and beneﬁts on the evolution of ventricular
remodeling in humans. Pharmacological targeting of the circadian mechanism can be given in vivo, after mI/R and alongside
conventional therapies, and is highly effective for improving
outcomes.
Results
Short-term in vivo SR9009 treatment post-reperfusion limits
HF. We postulated that pharmacological targeting of REV-ERB
after myocardial ischemia–reperfusion downregulates the NLRP3
inﬂammasome, leading to less reperfusion injury, reduced cardiac
remodeling, and protects against heart failure (HF). To test this,
we ﬁrst used a murine model of the left anterior descending
coronary artery ligation and reperfusion (mI/R), and treated with
the REV-ERB agonist SR9009 for the ﬁrst 5 days after mI/R, and
followed pathophysiology outcomes to 8 weeks HF (Fig. 1a).
Initial infarct size was consistent among mice, as expected, as
measured by Evans Blue and tetrazolium chloride (TTC) staining
(Fig. 1b). Importantly, even though all infarcts started the same,
those in the SR9009-treated mI/R group developed signiﬁcantly
2

Table 1 Short-term treatment with the REV-ERB agonist
SR9009 post-mI/R beneﬁts long-term cardiac structure and
function
mI/R+SR9009 mI/R+vehicle
n
10
10
Echocardiography baseline
LVIDd (mm)
4.02 ± 0.02
4.01 ± 0.02
LVIDs (mm)
2.41 ± 0.03
2.43 ± 0.04
EF (%)
76.81 ± 0.60
76.21 ± 0.87
FS (%)
39.91 ± 0.53
39.75 ± 0.64
HR (bpm)
472 ± 5
472 ± 4
1 week post-mI/R
LVIDd (mm)
4.14 ± 0.04*
4.49 ± 0.11
LVIDs (mm)
2.65 ± 0.05*
3.23 ± 0.14
EF (%)
72.31 ± 0.87*
60.75 ± 2.24
FS (%)
36.15 ± 0.68*
28.22 ± 1.54
HR (bpm)
455 ± 7
460 ± 8
4 weeks post-mI/R
LVIDd (mm)
4.35 ± 0.03*
4.80 ± 0.09
LVIDs (mm)
2.90 ± 0.04*
3.65 ± 0.10
EF (%)
68.37 ± 0.82*
53.84 ± 1.44
FS (%)
33.14 ± 0.57*
23.92 ± 0.79
HR (bpm)
468 ± 4
469 ± 5
8 weeks post-mI/R
LVIDd (mm)
4.38 ± 0.04*
4.92 ± 0.11
LVIDs (mm)
2.99 ± 0.07*
3.77 ± 0.12
EF (%)
66.44 ± 1.67*
53.31 ± 1.46
FS (%)
31.93 ± 1.15*
23.61 ± 0.84
HR (bpm)
461 ± 9
449 ± 4
Hemodynamics and morphometry 8 weeks post-mI/R
LVESP (mmHg)
97.11 ± 1.29*
91.43 ± 1.03
LVEDP (mmHg)
1.66 ± 0.84
1.83 ± 0.62
LVESV (μl)
17.83 ± 1.15*
28.58 ± 1.70
LVEDV (μl)
42.02 ± 1.04*
48.90 ± 1.30
SV (μl)
24.19 ± 0.68*
20.32 ± 0.79
12.16 ± 0.47*
9.97 ± 0.32
CO (mL min−1)
9302 ± 339*
7275 ± 358
+dP/dtmax
(mmHg s−1)
−8543 ± 223*
−6621 ± 374
−dP/dtmin
(mmHg s−1)
SBP (mmHg)
95.87 ± 0.86*
91.12 ± 0.66
DBP (mmHg)
58.67 ± 0.79
57.28 ± 1.31
MAP (mmHg)
70.34 ± 0.61
67.88 ± 0.95
HW (mg)
125.30 ± 1.77*
136.10 ± 2.03
4.35 ± 0.09*
4.64 ± 0.06
HW:BW (mg g−1)
BW (g)
28.89 ± 0.64
29.37 ± 0.48
HR (bpm)
503 ± 13
495 ± 22

Sham
6
4.02 ± 0.03
2.39 ± 0.03
77.76 ± 0.53
40.69 ± 0.50
468 ± 7
4.01 ± 0.03
2.38 ± 0.02
77.55 ± 0.49
40.54 ± 0.44
474 ± 7
4.05 ± 0.03
2.43 ± 0.03
76.78 ± 0.58
39.81 ± 0.53
485 ± 5
4.05 ± 0.04
2.39 ± 0.03
78.10 ± 0.48
40.99 ± 0.45
471 ± 3
98.09 ± 2.14
0.04 ± 0.55
10.85 ± 0.68
37.19 ± 0.96
26.34 ± 0.64
13.33 ± 0.64
10093 ± 819
−9262 ± 517
97.76 ± 1.24
61.93 ± 1.40
72.91 ± 1.15
118.00 ± 1.00
3.96 ± 0.12
30.02 ± 1.01
506 ± 18

LVIDd left ventricle internal dimensions at diastole, LVIDs LV internal dimensions at systole, % EF
% ejection fraction, % FS % fractional shortening, HR heart rate, LVESP left ventricle (LV) end
systolic pressure, LVEDP LV end diastolic pressure, LVESV LV end systolic volume, LVEDV LV
end diastolic volume, SV stroke volume, CO cardiac output, dP/dtmax and dP/dtmin maximum and
minimum ﬁrst derivative of LV pressure, SBP systolic blood pressure, DBP diastolic blood
pressure, MAP mean arterial pressure, HW heart weight, BW body weight
n = 8 mI/R+SR9009, mI/R+vehicle, n = 6 sham for hemodynamics. *p < 0.05 mI/R
+SR9009 vs. mI/R+vehicle, by Student’s t test. Values are mean ± SEM

less (p < 0.01) cardiac hypertrophy versus those in the mI/R
+vehicle group, as indicated by smaller heart weight (HW) and
HW-to-body weight ratios (HW:BW) by 8 weeks HF (Fig. 1c).
Thus these data suggest that short-term SR9009 treatment targeting REV-ERB after mI/R is protective and beneﬁts long-term
outcome.
To examine whether these treatment-dependent differences in
cardiac enlargement post-mI/R correlate with in vivo structure
and function changes, we performed echocardiography. Figure 1d
and Table 1 show that the mI/R mice treated short-term
with SR9009 developed signiﬁcantly (p < 0.0001) less adverse
remodeling with smaller left ventricular (LV) internal diastolic
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(LVIDd) and systolic (LVIDs) dimensions, along with better %
ejection fraction (% EF) and % fractional shortening (% FS) by
8 weeks HF, as compared with vehicle-treated controls. Thus
consistent with the heart size measurements, treatment with
SR9009 for just the ﬁrst few days after mI/R protects against
adverse cardiac remodeling after reperfusion, and reduces
progression to HF.
To establish whether these functional improvements in the
SR9009-treated group were also associated with better cardiac

hemodynamic responses, we next measured these in vivo. The
SR9009-treated mI/R mice had signiﬁcantly (p < 0.005) better LV
end systolic pressure (LVESP) and end systolic (LVESV) and
diastolic (LVEDV) volumes compared with the vehicle-treated
controls (Table 1, Fig. 1e). Consistent with the better cardiac
hemodynamics, these mice also exhibited better (p < 0.005) stroke
volume, cardiac output, dP/dtmax and dP/dtmin values, and blood
pressure as compared with vehicle-treated controls (Table 1).
Thus short-term treatment with SR9009 results in better cardiac
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Fig. 1 Short-term pharmacological targeting of REV-ERB after mI/R protects against HF. a Experimental design, left anterior descending coronary artery
ligation for 45 min of ischemia followed by reperfusion and SR9009 treatment (i.p. once daily at ZT06 for up to 5 days), and pathophysiologic assessments
up to 8 weeks post-mI/R. b All infarcts were reproducibly similar within the ﬁrst day post-mI/R, as quantiﬁed by area at risk:left ventricle (AAR:LV), infarct
area:LV (IN:LV), and infarct area:area at risk (IN:AAR) (n = 5 hearts/group). c mI/R mice treated with SR9009 for just 5 days had reduced heart weight
(HW) and HW:body weight (BW) vs. mI/R+vehicle controls, at 8 weeks post-mI/R (see Table 1 for details). *p < 0.01 mI/R+SR9009 vs. mI/R+vehicle.
d Functional beneﬁts of short-term SR9009 treatment after mI/R include smaller LV diastolic (LVIDd) and systolic (LVIDs) dimensions and better %
ejection fraction (% EF) and % fractional shortening (% FS), as compared with mI/R+vehicle, by echocardiography over 8 weeks post-mI/R (see Table 1
for all echocardiography values). *p < 0.0001 mI/R+SR9009 vs. mI/R+vehicle. e Preserved normal pressure–volume (PV) dynamics in SR9009-treated
mI/R mice, as compared with mI/R+vehicle, representative image (see Table 1 for all hemodynamics values). f Representative hearts showing cardiac
morphology in sham (top panel) and mI/R mice. The SR9009-treated mI/R hearts have less hypertrophy (less equidistant sections; middle panels), as
compared with mI/R+vehicle mice (more equidistant sections; bottom panels). Heart sections are collected every 300 µm. Sections are stained with
Masson’s trichrome. g The LV wall of sections #5 (s5) and #6 (s6) (from Fig. 1f) are shown with increased magniﬁcation to highlight comparisons in the
infarct region. Top panel, normal LV wall in sham mice. Middle panel, transmural infarct in LV wall of mI/R hearts, as indicated by the blue-staining region.
Bottom panel, animals treated short-term with SR9009 after mI/R have reduced infarct expansion by 8 weeks after mI/R. Scale bar (top right of each
paired image) = 500 μm. h Quantiﬁcation demonstrating that there is signiﬁcantly (*p < 0.001) less infarct volume and infarct expansion in the SR9009treated hearts by 8 weeks post-mI/R

function and reduced progression to HF as compared with mice
not given the drug in the early days post-mI/R.
In view of the better cardiac function in the SR9009-treated
mice, we next investigated whether this was associated with
reduced cardiac remodeling and less infarct expansion. Histopathology revealed that SR9009-treated mice developed less
cardiac hypertrophy (fewer equidistant sections) by 8 weeks HF
versus vehicle-treated controls (Fig. 1f). Moreover, the treatment
clearly prevented consequent damage to the LV infarct region,
versus controls. As shown in Fig. 1g, a normal LV wall in mice is
comprised of healthy myocardium (top panels), whereas the LV
wall in the mI/R + vehicle mice exhibited clear transmural
infarcts by 8 weeks HF (middle panels). In contrast, the LV
infarct expansion was greatly limited in the SR9009-treated mI/R
mice (lower panel); indeed, the myocardium appeared almost as
healthy as that of shams with no infarct at all. Moreover, the
SR9009-treated group had signiﬁcantly (p < 0.001) smaller infarct
volumes and reduced infarct expansion as compared with the mI/
R + vehicle group at 8 weeks after mI/R, and consistent with the
improved outcomes (Fig. 1h). Thus collectively these functional
and structural data demonstrate clear protection and that SR9009
given for just the ﬁrst few days after reperfusion leads to reduced
infarct expansion, better outcomes, and limits progression to HF.
Pharmacological targeting of REV-ERB in the healing heart.
To investigate the early mechanisms responsible, we ﬁrst showed
that SR9009 treatment downregulates Rev-Erb in the heart. We
found that SR9009 treatment of normal mice decreased (p < 0.05)
Rev-Erbα and Rev-Erbβ mRNA (Fig. 2a) and protein (Fig. 2b)
expression in the heart, as compared with vehicle-treated controls. Moreover, we found that SR9009 treatment post-mI/R also
decreased (p < 0.05) expression of both Rev-Erbα and Rev-Erbβ in
the infarcted heart over all 5 days of treatment (Fig. 2c), consistent with the notion that the drug targets the circadian
mechanism to improve outcomes (Fig. 2a–c; Supplementary
Table 1). Next, since the circadian mechanism plays a role in
modulating immune responses in the infarcted myocardium, we
examined whether treatment with SR9009 also led to decreased
inﬂammatory cytokine mRNA responses in the infarcted heart.
As early as 1 day post-mI/R, cytokine mRNA levels were less (p <
0.05) in the SR9009-treated hearts, with less expression of
monocyte chemoattractant protein 1 (Mcp1)/chemokine (C–C
motif) ligand 2 [Ccl2] mRNA, (p < 0.05) interleukin 6 (Il-6)
mRNA, and (p < 0.05) Ccl7 mRNA as compared with vehicletreated mI/R controls (Fig. 2d). Moreover, there was less cytokine
mRNA expression in the hearts of SR9009-treated mice for all
5 days of treatment compared with vehicle-treated controls,
4

covering the critical period of reperfusion injury (Fig. 2d; Supplementary Table 1).
SR9009 post-reperfusion reduces inﬂammatory responses in
the heart. Immune responses in the ﬁrst few days post-mI/R
trigger infarct expansion. In order to determine the effect of
SR9009 on mitigating these responses, we looked at inﬂammatory
cell inﬁltration to the heart in the early days post-mI/R. We found
less immunocyte recruitment following treatment with SR9009.
We ﬁrst investigated cardiac neutrophil recruitment by myeloperoxidase (MPO) activity; MPO is carried by neutrophil cells
and thus serves as a biochemical marker of inﬁltration. Figure 2e
shows that, compared with controls, the SR9009-treated mice had
an attenuated response with less (p < 0.01) MPO activity in the
heart at day 2 (25.17 ± 1.03 versus 39.96 ± 4.94 ng per mL per 100
mg tissue) and day 3 (18.46 ± 2.20 versus 25.23 ± 1.62 ng per mL
per 100 mg tissue), further supporting the notion of reduced
myocardial neutrophil recruitment in the SR9009-treated mice.
Consistent with MPO as a surrogate marker of cellular reperfusion responses in LV remodeling post-mI/R, the sham mice had
only minimal levels of activity in the heart (Fig. 2e). Thus these
data show that targeting the circadian mechanism decreases
inﬂammatory post-mI/R cellular responses to reduce infarct
expansion.
To provide a more robust and deﬁnitive assessment of postreperfusion cardiac inﬂammation, we next measured the total
leukocyte, macrophage, and T cell inﬁltration in the mI/R
myocardium by ﬂow cytometry (Fig. 2; Supplementary Table 2,
Supplementary Fig. 1). Overall, fewer (p < 0.001) leukocytes
(CD45+) inﬁltrated the infarcted myocardium at day 3 postmI/R with SR9009 treatment (Fig. 2f), consistent with downregulation of the inﬂammatory reperfusion response. We next
examined the macrophage response in mI/R+SR9009 hearts, by
ﬂow cytometry. As shown in Fig. 2g, treatment led to signiﬁcantly
(p < 0.001) less macrophage inﬁltration (CD11b+F4/80+) to the
infarcted myocardium for the ﬁrst 3 days post-mI/R. Importantly,
there were fewer (p < 0.001) cells of both the M1 (CD206-) and
M2 (CD206+) subpopulation types following treatment with
SR9009 (Fig. 2h). Moreover, there was also a higher proportion of
reparative M2 type macrophages following SR9009 treatment, as
compared with more adverse inﬂammatory M1 types in the
untreated controls (Fig. 2i).
We also investigated adaptive (T cell) responses following
treatment. We injected ﬂuorescent particles into the LV wall at
the time of surgery, and tracked outcomes using ﬂow cytometry.
We found that although the same proportion of myeloid cells
(CD11b+) within the heart took up the particles, there was
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compared with the lymph nodes from mI/R + vehicle controls
(Fig. 2j). Since T cells are activated in the mediastinal lymph
nodes (Supplementary Fig. 2), this suggests the possibility of less
overall activation of T cells following SR9009 treatment in vivo.
Consistent with this notion, we found signiﬁcantly (p < 0.001) less
proliferation of T cells (CD3+CD4+Ki67+) in the mediastinal
lymph node (Fig. 2k), and ultimately signiﬁcantly (p < 0.001) less
T cell inﬁltration in infarcted myocardium by day 3 (Fig. 2l;
Supplementary Table 2). Taken together, our ﬁndings suggest
that pharmacological targeting of the circadian factor REV-ERB
for just the ﬁrst few days after mI/R decreases both the innate and
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the subsequent adaptive inﬂammatory responses in the infarcted
heart post-mI/R, and that this reduction leads to reduced infarct
expansion and better outcomes.
SR9009 post-reperfusion reduces the adverse NLRP3 inﬂammasome. The adverse NLRP3 inﬂammasome is integral to mI/R
injury; it exacerbates myocardial damage. We postulated that
REV-ERB activation with SR9009 would decrease the production
of its molecular output NLRP3, which would contribute to the
improved outcomes. Consistent with this notion, we show that
SR9009-treated mice have decreased (p < 0.01) expression of the
REV-ERB molecular output Nlrp3 mRNA (Fig. 3a) and protein
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Fig. 2 Short-term pharmacological targeting of REV-ERB beneﬁts outcome post-mI/R by limiting inﬂammatory responses in infarcted myocardium.
a SR9009 reduced cardiac Rev-Erbα and Rev-Erbβ mRNA expression and b protein abundance by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and western blot as quantiﬁed in vivo, ZT07, *p < 0.05 (n = 4 hearts/group). c SR9009 treatment for 5 days (green line)
post-mI/R reduced Rev-Erbα and Rev-Erbβ mRNA expression in infarcted hearts only during the time of treatment, and d cardiac cytokine mRNA
expression was also reduced in infarcted hearts, *p < 0.05 (n = 5 hearts/time point/group), see Supplementary Table 1 for RT-PCR values. e Neutrophil
recruitment to the infarcted myocardium was reduced with SR9009 treatment vs. mI/R + vehicle by myeloperoxidase (MPO) assay (*p < 0.01, n = 5
hearts/time point/group). f Fewer leukocytes inﬁltrated infarcted myocardium following SR9009 treatment, as shown by ﬂow-cytometry staining of
CD45+ cells, and g less macrophages (CD11b+F4/80+) inﬁltrated, including both the (h) M1 (CD206−) and M2 (CD206+) subpopulations as compared
with mI/R + vehicle controls, and i the proportion of reparative M2 cells over the adverse M1 macrophages was higher in SR9009-treated mice consistent
with the improved outcomes (*p < 0.001, n = 5 hearts/time point/group). See Supplementary Fig. 1 for leukocyte gating, and Supplementary Table 2 for
leukocyte values. j To assess T cell responses, we ﬁrst injected ﬂuorescent particles into the anterior free LV wall at the time of surgery, which are taken up
by CD11b+ myeloid cells, and trafﬁcked to the mediastinal lymph nodes (Supplementary Fig. 2). SR9009-treated mice had reduced trafﬁcking to the heartdraining mediastinal lymph nodes by day 1, k resulting in less proliferation of Ki67+ lymphatic CD4+ T cells, and l reduced adverse T cell inﬁltration in the
infarcted myocardium by day 3 (*p < 0.001, n ≥ 4 hearts/group)

(Fig. 3b) expression in the heart as early as 1 day post-mI/R.
Moreover, we also observed decreased (p < 0.01) production of
the REV-ERB molecular outputs Il-1β mRNA (Fig. 3c) and
protein (Fig. 3d), and Il-18 mRNA (Fig. 3e) and protein (Fig. 3f),
which along with NLRP3 contribute to inﬂammasome formation.
Thus, at as early as 1 day post-mI/R, SR9009 treatment limits the
induction of the adverse NLRP3 inﬂammasome, reducing myocardial damage.
Genetic circadian models of loss and gain of function. SR9009
enhances REV-ERB repressor activity and this provides a
mechanism through which SR9009 protects against adverse remodeling post-mI/R, as shown above. Conversely then, one would
anticipate that loss of SR9009’s target REV-ERB would abolish the
protective beneﬁts of SR9009 treatment. To explore this, we used
REV-ERB (Nr1d1−/−) mice. Genotyping and running wheel actigraphy are shown in Fig. 3g. The Nr1d1−/− mice were subjected to
mI/R, treated with SR9009, and pathophysiology measured. The
Nr1d1−/− mice were susceptible to HF, with increased LVIDd and
LVIDs and decreased % EF and % FS by 4 weeks post-mI/R; they
develop HF similar to WT mI/R littermates (Fig. 3h; Supplementary
Table 3). As anticipated, we found no protective beneﬁts of SR9009
in the Nr1d1−/− mice lacking the REV-ERB target. Indeed, the
Nr1d1−/− mI/R mice treated with SR9009 were not different than
the Nr1d1−/− mI/R vehicle controls, or the WT-mI/R littermate
controls, consistent with the notion that a functional REV-ERB
target is necessary for SR9009 efﬁcacy (Fig. 3h; Supplementary
Table 3). Moreover, SR9009 treatment only attenuated (p < 0.05)
cytokine and inﬂammasome mRNA expression in WT mice with a
REV-ERB target, but not in the Nr1d1−/− mice lacking the REVERB target (Fig. 3i). Similarly, loss of REV-ERB led to increased
expression of Nlrp3, Il-1β, and Il-18 in Nr1d1−/− cardiac ﬁbroblasts
in vitro, consistent with a loss of repressor activity (Fig. 3j).
Moreover, while lipopolysaccharide (LPS) similarly stimulated the
inﬂammasome in in vitro cardiac ﬁbroblasts derived from WT or
Nr1d1−/− knockout hearts (Fig. 3k), SR9009 was more effective at
reducing the inﬂammasome expression in WTs as compared with
Nr1d1−/− cells lacking the REV-ERB target (Fig. 3l). As a corollary
to the genetic loss-of-function studies using the Nr1d1 mice, we also
studied mI/R responses using ClockΔ19/Δ19 mice, as a model of
genetic gain of REV-ERB repressor activity. ClockΔ19/Δ19 mI/R mice
showed better cardiac structure and function as compared with WT
mI/R controls, with comparable beneﬁt to that observed in SR9009treated mI/R mice (Supplementary Fig. 3, Supplementary Table 4).
Moreover, ClockΔ19/Δ19 mI/R mice also showed less inﬁltration of
leukocytes (CD45+), macrophages (CD11b+F4/80+), and T cells
(CD4+) to the infarcted myocardium as compared with hearts from
WT mI/R mice (Supplementary Fig. 3, Supplementary Table 5),
consistent with REV-ERB activation. Thus collectively these data
6

are consistent with the notion that targeting the circadian
mechanism is sufﬁcient to reduce inﬂammation in the infarcted
myocardium, mediated by downregulation of the inﬂammasome
sensor in the heart.
Identifying cellular targets of SR9009 treatment post-mI/R. We
investigated which cellular targets mediate the protective beneﬁts of
SR9009: immune cells, cardiac myocytes, or cardiac ﬁbroblasts.
First, we investigated the immune cells, by performing adoptive
transfer experiments using Nr1d1−/− mice to generate bone marrow transplant (BMT) chimeric mice. The experimental design to
generate these mice (BMTWT→WT and BMTNr1d1−/−→WT) is
illustrated in Fig. 4a. To verify the reconstitution of bone marrow
after transplantation, we validated the presence of CD45.2+ donor
cells in the blood and bone marrow of the BMT mice (Fig. 4b).
Flow-cytometry analysis showed that peripheral blood and bone
marrow cells consisted of > 96% donor cells by 8 weeks after BMT.
These mice were then subjected to mI/R, treated with SR9009 or
vehicle, and initial infarct size (Fig. 4c) and inﬂammasome and
cytokine expression (Fig. 4d) were determined. We found that
SR9009 works in WT mice transplanted with Nr1d1−/− bone
marrow, similar to the WT control mice, suggesting that immune
cells in this context are not the primary protective targets of SR9009
treatment. Second, we investigated the cardiac myocytes as cellular
targets, by performing viability assays in vitro under normal and
hypoxia/reoxygenation conditions. We found that SR9009 treatment did not signiﬁcantly rescue cardiomyocyte cell death under
any conditions (Fig. 4e), suggesting that cardiomyocytes in this
context are also not the primary protective targets of SR9009
treatment. Third, we investigated the cardiac ﬁbroblasts as cellular
targets by stimulating the cells with LPS in vitro, and then assaying
formation and activity of the inﬂammasome. We show that whereas
LPS induces expression of NLRP3 and IL-1β in cardiac ﬁbroblasts,
co-treatment with SR9009 protects against activation of the
inﬂammasome (Fig. 4f). Along with this reduced inﬂammasome
activity, there is also less mature IL-1β secreted from the cells
(Fig. 4g). Thus collectively these data suggest that cardiac ﬁbroblasts
are a cellular target that contributes to the protective beneﬁts of
SR9009 in the heart.
Timing of treatment (chronotherapy). Rev-Erbα and Rev-Erbβ
peak in the middle of murine sleep time (Supplementary Fig. 4)
and thus we postulated that SR9009 treatment would be most
effective around the time-of-day when its target is highest. To test
this, mice were divided into four groups: (i) mI/R at sleep time,
followed by SR9009 at reperfusion (ZT06, 5 days at ZT06); (ii)
mI/R at wake time, followed by SR9009 at reperfusion (ZT18,
then 5 days at ZT18); (iii) mI/R at wake time, followed by SR9009
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at reperfusion (ZT18) and the following 5 days at ZT06; and (iv)
mI/R at wake time, vehicle control. To assess the beneﬁts of
SR9009 on preventing progression to HF, mice were followed by
pathophysiologic assessments for 8 weeks post-mI/R (Fig. 5a;
Supplementary Table 6). We found that when mI/R occurred at
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sleep time, treatment at sleep time had the greatest beneﬁt on
healing, consistent with our notion that treatment corresponding
to the peak time of Rev-Erb expression is most effective. When
mI/R occurred at wake time, an initial treatment at the time of
reperfusion followed by subsequent treatment at sleep time was
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Fig. 3 SR9009 reduces the adverse NLRP3 inﬂammasome, and genetic loss of REV-ERB repressor activity. a SR9009 treatment reduced cardiac Nlrp3
mRNA expression, and b protein abundance as early as 1 day post-mI/R as compared with vehicle-treated controls, *p < 0.01. SR9009 treatment also
reduced inﬂammasome cytokines in the heart, including c Il-1β mRNA expression and d IL-1β protein, and e Il-18 mRNA expression and f IL-18 protein
abundance versus controls, ZT07, *p < 0.01 (n = 5 hearts/group). g Representative genotyping of homozygous Nr1d1−/−, heterozygous Nr1d1+/−, and WT
Nr1d1+/+ mice (top), and wheel running actigraphy (bottom) of mice under diurnal (12 h light:12 h dark; LD) and circadian (constant darkness; DD)
conditions. Nr1d1−/− mice exhibited a shortened free-running circadian period, as anticipated. h Homozygous (Nr1d1−/−) mice lacking REV-ERB were
not protected by treatment with the REV-ERB agonist SR9009, with no beneﬁts on cardiac structure and function post-mI/R as compared with WT
littermates with a functional target, see Supplementary Table 3 for pathophysiology values. i Treatment with SR9009 also showed no beneﬁts on the
hearts of Nr1d1−/− mice for inﬂammatory cytokine mRNA expression nor NLRP3 inﬂammasome expression as compared with WT littermates (ΔΔCT,
*p < 0.05, n = 4 hearts/group). j Nr1d1−/− cardiac ﬁbroblasts in culture exhibited increased expression of Nlrp3, Il-1β, and Il-18 (inﬂammasome)
mRNA levels, consistent with a loss of REV-ERB repressor activity, and k LPS stimulated the inﬂammasome in cardiac ﬁbroblasts isolated from Nr1d1+/+ or
Nr1d1−/− mice, and l SR9009 was most effective at reducing the inﬂammasome activation in the Nr1d1+/+ cells with a functional REV-ERB target (1/CT,
*p < 0.05, n = 4/group). See Supplementary Tables 3, 4, 5, and Supplementary Fig. 3 for genetic (Nr1d1, ClockΔ19/Δ19) loss and gain of function studies

Table 2 One day of SR9009 treatment beneﬁts long-term cardiac structure and function post-mI/R

n
Echocardiography baseline
LVIDd (mm)
LVIDs (mm)
EF (%)
FS (%)
HR (bpm)
BW (g)
1 week post-mI/R
LVIDd (mm)
LVIDs (mm)
EF (%)
FS (%)
HR (bpm)
4 weeks post-mI/R
LVIDd (mm)
LVIDs (mm)
EF (%)
FS (%)
HR (bpm)
Morphometry
HW (mg)
HW:BW (mg g−1)
HW:TL (mg mm−1)
BW (g)

mI/R + SR9009 (1 day)
6

mI/R + SR9009 (3 days)
6

mI/R + SR9009 (5 days)
6

mI/R + vehicle
6

3.99 ± 0.02
2.42 ± 0.03
76.30 ± 0.72
39.44 ± 0.61
460 ± 13
22.73 ± 0.77

4.01 ± 0.02
2.43 ± 0.03
76.06 ± 0.46
39.45 ± 0.53
483 ± 8
23.38 ± 0.80

4.01 ± 0.04
2.38 ± 0.03
77.58 ± 0.43
40.59 ± 0.39
476 ± 3
21.90 ± 0.35

3.99 ± 0.02
2.40 ± 0.04
77.12 ± 0.90
40.32 ± 0.72
467 ± 4
23.42 ± 0.97

4.28 ± 0.03
2.82 ± 0.02
69.80 ± 0.40
34.20 ± 0.30
463 ± 6

4.23 ± 0.03
2.70 ± 0.02
72.40 ± 0.37
36.27 ± 0.29
480 ± 6

4.13 ± 0.02
2.61 ± 0.03
73.18 ± 0.71
36.80 ± 0.59
464 ± 6

4.43 ± 0.02**
3.22 ± 0.04**
59.91 ± 1.03**
27.46 ± 0.63**
456 ± 6

4.34 ± 0.01
2.90 ± 0.02
68.51 ± 0.66
33.34 ± 0.46
448 ± 6

4.33 ± 0.01
2.87 ± 0.02
69.09 ± 0.37
33.71 ± 0.26
464 ± 8

4.31 ± 0.01
2.85 ± 0.02
69.25 ± 0.71
33.82 ± 0.52
470 ± 3

4.71 ± 0.04**
3.56 ± 0.04**
54.73 ± 0.73**
24.32 ± 0.42**
471 ± 4

125.67 ± 3.62
4.50 ± 0.09
6.19 ± 0.15
27.90 ± 0.59

124.50 ± 2.79
4.52 ± 0.06
6.15 ± 0.13
27.52 ± 0.52

123.33 ± 1.41
4.36 ± 0.11
6.11 ± 0.07
28.35 ± 0.82

135.67 ± 1.88**
4.73 ± 0.04*
6.68 ± 0.11**
28.69 ± 0.44

LVIDd left ventricle internal dimensions at diastole, LVIDs LV internal dimensions at systole, % EF % ejection fraction, % FS % fractional shortening, HR heart rate, HW heart weight, BW body weight, TL
tibia length
*p < 0.05, **p < 0.01, mI/R + vehicle vs. all groups by ANOVA. Values are mean ± SEM

similarly beneﬁcial. This is important because humans may
experience an MI at any time of day, and thus the ﬁrst treatment
can be given with reperfusion, and subsequently corresponding to
the time of peak Rev-Erb expression, to maximize therapeutic
beneﬁts.
SR9009 treatment for just 1 day protects against heart failure.
Finally, we investigated the shortest treatment window needed to
beneﬁt long-term outcome. Since giving the drug at the time of
reperfusion, and then just one subsequent day of SR9009 treatment post-mI/R attenuates the inﬂammasome (Fig. 3a–f), we
postulated that only 1 day of treatment was needed to promote
efﬁcient healing long-term. To assess the minimum treatment
regimen, mice were randomized to receive SR9009 at ZT06 at the
time of reperfusion, followed by an additional treatment at ZT06
for 1 day, 3 days, or 5 days post-mI/R, and long-term outcomes
were measured by pathophysiology. We found that just 1 day of
SR9009 treatment signiﬁcantly (p < 0.001) beneﬁtted cardiac
structure and function and prevented progression to HF (Fig. 5b,
8

Table 2). Moreover, the beneﬁts observed with just 1 day of
SR9009 treatment were similar to those observed with 3 or 5 days
of treatment, consistent with the notion that the beneﬁts conferred occur within the ﬁrst day after mI/R (black arrows, Fig. 5b).
These ﬁndings are very promising because they suggest that
only a very short treatment window of 1 day will reduce the
adverse inﬂammasome, and create a better foundation to reduce
infarct expansion, remodeling, and protect against heart failure
(Fig. 5c).
Collectively, we show using both pharmacologic and genetic
approaches that short-term targeting of the circadian mechanism
in vivo and post-mI/R beneﬁts outcome. As illustrated in Fig. 5c,
SR9009 targets Rev-Erb and activates repressor activity leading to
decreased priming of genes under its transcriptional control. This
includes the Nlrp3 inﬂammasome, leading to reduced adverse
innate and adaptive post-reperfusion inﬂammatory responses,
thereby protecting against infarct expansion and left ventricular
remodeling, and thus beneﬁting heart structure and function and
protecting against heart failure.
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Fig. 4 Cellular beneﬁts of SR9009 treatment post-mI/R. a To investigate the role of immune cells, lethally irradiated WT (CD45.1+) mice were
reconstituted with bone marrow cells from WT or Nr1d1−/− donor (CD45.2+) mice, generating bone marrow transplant BMTWT→WT or BMTNr1d1−/−→WT
chimeras. b Peripheral blood mononuclear cells (PBMCs) and bone marrow cells had >96% reconstitution with CD45.2+ donor cells, at 8 weeks after BMT
by ﬂow cytometry (n ≥ 5/group). BMT mice were subjected to mI/R and treatment with SR9009, and c infarct size by day 2 was signiﬁcantly reduced, and
d there was less activation of cardiac inﬂammasome and cytokine mRNA expression versus vehicle-treated controls, ZT07, *p < 0.05 (n = 5 hearts/group).
e Cardiomyocytes treated with SR9009 showed no difference in hypoxia-induced cell death versus vehicle-treated controls (n = 6/group). f LPS activates
the inﬂammasome in cardiac ﬁbroblasts, and co-treatment with SR9009 decreased levels in the cells, and g supernatant, *p < 0.05 (n = 4/group)

Discussion
We found, in a murine model of mI/R using pharmacological and
genetic approaches, that as little as 1 day of targeting of the circadian
mechanism in vivo and post-mI/R reduces infarct expansion and
prevents heart failure. As illustrated in Fig. 5c, our data show that

SR9009 treatment at ZT06 for just 1 day post-mI/R enhanced REVERB repressor activity and led to downregulation of cardiac NLRP3,
IL-1β, and IL-18. These are critical constituents of the NLRP3
inﬂammasome; SR9009 treatment reduced inﬂammasome activity.
Downregulation of the inﬂammasome subsequently limited
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Fig. 5 Treatment with SR9009 is time-of-day dependent, and treatment for just 1 day leads to improved outcomes post-mI/R. a Mice subjected to mI/R
during their sleep time (ZT01-04) or wake time (ZT13-16) were chronotherapeutically treated with SR9009 at time points corresponding to the peak
(ZT06) or trough (ZT18) of cardiac REV-ERB expression (see Supplementary Fig. 4). First or subsequent treatments at sleep time (ZT06) were most
effective; see Supplementary Table 6 for all pathophysiology values. b Mice were subjected to mI/R (ZT01-04) and treated with SR9009 (ZT06) for 1, 3, or
5 days. Just 1 day of SR9009 treatment was sufﬁcient to beneﬁt outcomes versus vehicle-treated control; see Table 2 for pathophysiology data. c Proposed
mechanism for the beneﬁcial effects of targeting REV-ERB post-mI/R. SR9009 enhances REV-ERB repressor activity leading to reduced NLRP3
inﬂammasome priming and activation in the infarcted myocardium post reperfusion, leading to more efﬁcient repair processes and protecting against HF
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recruitment of inﬂammatory cells and mediators in infarcted
myocardium, and laid a better foundation for healing, resulting in
reduced infarct expansion and protection against HF. In contrast,
the untreated mI/R mice developed infarct expansion, adverse LV
remodeling, and clinically worse outcomes.
To our knowledge, this is the ﬁrst study using pharmacological
targeting of the circadian mechanism to reduce inﬂammasome
activity and inﬂammatory cells recruited to infarcted myocardium after reperfusion, leading to reduced cardiac remodeling
and infarct expansion, and protecting against heart failure in vivo.
Previously, we and others showed that Rev-Erb agonism with
SR9009 reduces cardiac hypertrophy in pressure overloadinduced cardiac hypertrophy in mice14,15. Also pre-treatment of
mice with SR9009 before acute myocardial infarction provides
protective beneﬁts16, although long-term prophylactic treatment
in real life may not be feasible. Montaigne et al. reported a timeof-day-effect on outcomes for patients undergoing aortic valve
replacement; their study linked Rev-Erb antagonism with upregulation of genes involved in cardiac remodeling ex vivo17. Here,
we use the clinically relevant myocardial ischemia reperfusion
model (mI/R), which simulates the beneﬁts of pharmacological
targeting of the circadian mechanism on the evolution of ventricular remodeling after heart attacks in humans. We show that
Rev-Erb agonism reduces formation of the adverse NLRP3
inﬂammasome in vivo. Our approach is especially promising
because treatment is given only after myocardial infarction
occurs, and for only 1 day, and can be given alongside conventional therapies such as reperfusion to improve healing. Because
treatment limits the early adverse reperfusion injury, then the
infarct region of the LV is capable of intrinsically healing, and
subsequent LV remodeling and progression to heart failure (HF)
is prevented, which has important implications for patients that
could lead to longer and healthier lives.
Mechanistically, our results show that the beneﬁts of pharmacologically targeting the circadian mechanism coincide with an
observed decrease in the NLRP3 inﬂammasome. The inﬂammasome is a natural damage sensor that is activated in response to
noninfectious stimuli such as cardiomyocyte debris following
infarction. It triggers the immune system to clear the debris;
however, in doing so it is well documented to exacerbate myocardial damage via local immune cell responders and released
cytokines and other mediators18,19. As has been elegantly
reviewed by Toldo and Abbate20, recent experimental studies
have focussed on the NLRP3 inﬂammasome as an important new
therapeutic target to reduce reperfusion injury, infarct size, and
prevent the development of HF following myocardial infarction.
However, no selective NLRP3 inhibitors are clinically available for
use in patients at present, indeed studies identifying selective
NLRP3 inhibitors are eagerly anticipated20. Our ﬁndings here
reveal very promising results that SR9009 treatment for just 1 day
decreases formation of the cardiac NLRP3 inﬂammasome, leading
to reduced infarct expansion, and prevention of HF in mice.
There are several lines of evidence supporting a direct link
between pharmacologically targeting the circadian factor REVERB and downregulation of the NLRP3 inﬂammasome. Previous
studies by others showed that REV-ERB is a transcription factor
that negatively regulates NLRP3 in macrophages21,22, as well as
transcription of the proinﬂammatory cytokine IL-1β that is
subsequently processed by NLRP3 inﬂammasome activity21.
Treatment with the Rev-Erb agonist SR9009 decreases NLRP3
inﬂammasome in macrophages21,22. Conversely, it has been
shown that loss of REV-ERB leads to increased NLRP3, IL-1β,
and IL-18 in macrophages using REV-ERB knockout (Nr1d1−/−)
mice21,22. Moreover, here, we show that REV-ERB also appears to
regulate the NLRP3 inﬂammasome in the infarcted heart. First,
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treatment with SR9009 reduces the inﬂammasome and improves
HF outcomes in WT mice as compared with vehicle-treated
controls. Second, we found that treatment with the Rev-Erb
agonist SR9009 reduces Rev-Erb mRNA and protein in the
normal heart, and in the infarcted heart, and reduces NLRP3
mRNA and its constituent cytokine mRNA’s in the infarcted
heart. Third, we found no protective beneﬁts of SR9009 on HF
outcomes in Nr1d1−/− mice lacking the REV-ERB target, consistent with the notion that a functional REV-ERB target is
necessary for SR9009 efﬁcacy. Fourth, SR9009 treatment only
attenuated inﬂammasome expression in WT mice with a functional REV-ERB target, but not in the Nr1d1−/− mice lacking the
REV-ERB target. Fifth, loss of REV-ERB led to increased
expression of Nlrp3, Il-1β, and Il-18 in Nr1d1−/− cardiac ﬁbroblasts in vitro, consistent with a loss of repressor activity. Sixth,
SR9009 more effectively reduced inﬂammasome expression in
LPS-treated cardiac ﬁbroblasts from WTs as compared with
Nr1d1−/− cells lacking the REV-ERB target. Finally, targeting
REV-ERB is effective by day 1 and at sleep time, corresponding to
when REV-ERB is most abundant. Thus collectively, these data
support the notion that REV-ERB is a critical regulator of the
NLRP3 inﬂammasome, and thus a promising target for reducing
inﬂammasome-mediated reperfusion injury in the heart in the
ﬁrst few days post-mI/R to improve outcomes.
It is important to note that in this study we are not preventing
inﬂammation, only turning down the immune responses. A balance
is important because immune cells exhibit divergent functions, and
some responses are important for infarct repair6,7,11,23–26. For
example, the early responding neutrophils deposit MPO, a potent
enzyme to break down cellular debris, but this also becomes
involved in adverse remodeling after myocardial injury27–29.
Indeed, chronically elevated plasma MPO levels found in human
patients following ST-elevation myocardial infarction (STEMI) are
a predictor of poor outcome30. Here, we show that reducing the
NLRP3 inﬂammasome leads to less reperfusion injury: a decreased
cascade of the neutrophil, macrophage, and T cell recruitment to
the infarct region. The LV infarct can better heal, resulting in less
adverse remodeling, and protection against HF.
REV-ERB is a strong regulator of the inﬂammasome pathway,
and thus it presents as an ideal target for reducing reperfusion
injury responses post-mI/R. SR9009 exhibits speciﬁcity for REVERB, as the agonist has been pharmacologically tested against 48
nuclear receptors and shown to be selective for REV-ERB in these
studies13. Moreover, it has been tested in the NIH psychoactive
drug speciﬁcity panel (PDSP, https://pdsp.unc.edu) against an
array of GPCRs, transporters, and ion channels, with no signiﬁcant cross-reactivity13. This speciﬁcity is consistent with our
genetic data for loss and gain of function in the circadian mutant
and knockout mice. Interestingly, REV-ERB also binds naturally
occurring heme to modulate its activity31,32, Notably, reperfusion
hemorrhage with elevated heme levels is strongly associated with
worse outcomes post-mI/R33,34; thus it is tempting to speculate
that SR9009 may also work indirectly through displacement of
heme to provide additional beneﬁts to negate reperfusion injury.
This notion would be consistent with a recent report35, suggesting
that the beneﬁts of SR9009 may be attributed to strategies in
addition to direct modulation of REV-ERB activity. It would be
interesting to look at the relative effects on heme displacement
post-mI/R using REV-ERBα and/or REV-ERBβ mice in future
studies. In summary, these data identify REV-ERB as a pharmacological target to downregulate the NLRP3 inﬂammasome,
and possibly additional adverse immune responses, for mitigating
MI reperfusion injury and preventing HF.
MI is a well-recognized illness that triggers pathophysiologic
cascades leading to HF. There is an urgent public health need to
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prevent HF; it is a leading cause of hospitalization, an enormous
economic burden, and there is no known cure36–39. Infarct size is
a powerful predictor of death40. Infarct expansion can be reduced
by myocardial post-ischemia reperfusion, which is the timely
restoration of blood ﬂow to ischemic myocardium, for example
through percutaneous coronary intervention or angioplasty41,42.
However, even if reperfusion is successful, this triggers reperfusion injury; an adverse inﬂammatory response and many patients
continue to develop adverse remodeling leading to HF5,42. Previously, we and others showed that the circadian mechanism
plays a critical role in cardiac inﬂammation post-MI8,10,43,44. This
study now reveals that circadian pharmacology can target the
inﬂammasome to reduce reperfusion injury, presenting the possibility that we can intrinsically heal an MI. Notably, ischemia and
reperfusion injury also contribute to a wide range of cardiovascular pathologies (e.g., following organ transplantation, hypoxia,
valve replacement, post-ischemic arrhythmias)3,29, suggesting
potential for additional important therapeutic applications of
targeting REV-ERB even beyond ischemic heart disease and
infarct repair. With the aging of our population, and the emerging epidemic of cardiovascular disease, circadian medicine
strategies hold promise for reducing cardiovascular morbidity
and mortality, leading to longer healthier lives.
Collectively, our studies shed light on a critical role for REVERB in cardiac repair, and illustrate the importance of targeting
the circadian mechanism to reduce reperfusion injury post-MI
and prevent the development of HF. Our pharmacological
approach reduces adverse inﬂammasome activation, thereby
limiting cytokine and immune cell recruitment to the infarcted
myocardium, especially during the period of time when the
infarct is highly active biologically. This reduces stress on the
vulnerable infarct, limiting the profound and deleterious changes
in LV structure, and beneﬁts function after mI/R. These studies
have been done in mice, which bear some limitations, but at a
minimum the promising experimental results focus expectations
toward pharmacology that can beneﬁt patients with heart disease.
We hope our experimental study will stimulate the initiation of
translational research targeting REV-ERB, and indeed explore an
emerging class of drugs that target the circadian mechanism, to
beneﬁt treatment of patients clinically.
Methods
Experimental design. All animal work was conducted under the guidelines of the
Canadian Council on Animal Care. Brieﬂy, 8-week-old C57BL/6 mice (Charles
River) were housed in a 12-h light (L) and 12-h dark (D) cycle (12:12 LD) for
2 weeks prior to surgery. Mice were anaesthetized with isoﬂurane, intubated and
ventilated, and subjected to left anterior descending coronary artery ligation for 45
min, followed by reperfusion (mI/R model), and then maintained for 8 weeks
(heart failure (HF) model). Sham animals underwent the same surgical procedures,
but without coronary artery ligation. All surgeries were performed between ZT01
and ZT04, unless otherwise indicated, and all samples were collected for molecular
analyses at ZT07 unless otherwise noted. Following recovery from mI/R, the mice
were randomized to one of two groups. Either (i) they were given SR9009 (100 mg
per kg in 15% cremophor, once daily at ZT06), or (ii) were given vehicle only (15%
cremophor). Dosage was based on murine studies of in vivo efﬁcacy13,14,45. Following treatment (for 1 to 5 days as described in the studies), all groups were
maintained without any further drug treatments for up to 8 weeks post-mI/R. To
show that all infarcts started the same, hearts were collected within the ﬁrst day,
and Evans Blue and 2,3,5-triphenyltetrazolium chloride (TTC) staining was performed. Mice were then followed for pathophysiologic assessments to determine
the beneﬁts of SR9009 targeting of Rev-Erb on outcomes including by echocardiography (at baseline, 1, 4, and 8 weeks post-mI/R), morphometrics, in vivo
pressure–volume hemodynamics (8 weeks post-mI/R) and pathologic measures of
infarct volume and infarct expansion (8 weeks post-mI/R). Hearts from a separate
set of mice were collected for examining the effects of SR9009 on Rev-Erb cardiac
gene and protein expression. A third set of hearts were collected for examining how
targeting Rev-Erb modulated cytokine and inﬂammasome responses at 1, 2, 3, 5, 7,
and 14 days post-mI/R by real-time polymerase chain reaction (RT-PCR). A fourth
set of mice was used to quantify how targeting Rev-Erb affected cardiac immune
cell inﬁltration post-mI/R to beneﬁt outcome (cardiac myeloperoxidase marker of
12

myeloid cells; total leukocytes, macrophages, and T cell activation and inﬁltration).
A ﬁfth set were REV-ERB (Nr1d1−/−) knockout mice on a C57BL/6 background46,
that were maintained in our breeding colony. They were used to investigate the
effects of SR9009 treatment post-mI/R in the absence of REV-ERBα activity. A
sixth set were ClockΔ19/Δ19 mice47 (these are homozygous for the CLOCK point
mutation) bred on a C57Bl/6 background, our breeding colony is maintained in the
Central Animal Facilities at the University of Guelph10,14. These and wild-type
(WT) controls were used to investigate the link between SR9009 treatment and
REV-ERB activity for the beneﬁts of targeting the circadian mechanism to improve
outcomes after mI/R. These animals were divided into sets for use for determination of gene expression, infarct size after mI/R, pathophysiology and outcome,
and quantiﬁcation of leukocyte inﬁltration to the infarcted myocardium, as
described above. A seventh set of mice were used to investigate how time-of-day
and length of treatment inﬂuence cardiac inﬂammation and remodeling and
improved outcomes in HF. For the time-of-day chronotherapy studies, a subset of
mice were killed every 4 h for 24 h, and hearts collected to determine the diurnal
proﬁle and peak and trough timing of REV-ERB in the heart. All endpoints
assessed and n-values and statistics are provided in detail in the Figure legends and
the Supplementary information.
Animals. Male C57Bl/6 mice (Charles River, Quebec, Canada), and ClockΔ19/Δ19
mice47,48 (homozygous for the CLOCK point mutation, C57Bl/6 background) and
Nr1d1−/− mice46 (null mutation of Rev-Erb, C57Bl/6 background) were housed in
a 12 h light (L):12 h dark (D) cycle with lights on at 9:00 am (Zeitgeber time 0,
ZT0) and lights off at 9:00 pm (ZT12). All animals were housed at the Central
Animal Facility, University of Guelph. Standard rodent chow and water
were provided ad libitum throughout the study. All studies were approved by the
University of Guelph Institutional Animal Care and Use Committee, and the
Canadian Council on Animal Care guidelines. ClockΔ19/Δ19 and Nr1d1−/− mice
were genotyped by allele-speciﬁc PCR (see Supplementary Table 7 for primers).
Genotyping, and phenotyping of circadian locomotor activity using running wheel
actigraphy, was previously described14,48,49. Individually housed mice were
entrained to a diurnal 12:12 L:D cycle for 2 weeks, followed by transfer to constant
darkness (circadian cycle, DD). The data were analyzed using ClockLab
(ActiMetrics).
Myocardial ischemia/reperfusion. Eight-week-old mice (22-25 g) underwent
surgical ligation of the left anterior descending (LAD) coronary artery followed by
reperfusion. All surgeries were performed between ZT01-04, unless otherwise
described for the time-of-day experiments; for these, surgeries were either done
during the murine sleep time (ZT01-04) or murine wake time (ZT13-16) using our
established protocols43. Mice were anaesthetized with isoﬂurane, intubated, and
ventilated (Harvard Apparatus model 687; St Laurent, Quebec, Canada). Prior to
incision, animals were administered a local subcutaneous injection of a 50:50 mix
of bupivacaine (1.5 mg per kg) and lidocaine (3 mg per kg). A left-sided incision
was made in the third intercostal space to view the heart, and the pericardium was
gently dissected to expose the LAD. A silk 7–0 suture (Ethicon) was passed
underneath the LAD at 1 mm below the left auricle, and a 5 mm piece of PE-10
tubing was placed over the LAD. The suture was tied around the tubing and LAD
to induce ischemia for a 45- min period. The chest was temporarily closed, and a
sterile cloth placed over the incision site. After 45 min, the site was re-exposed and
the tubing and suture were removed to allow for LAD reperfusion. The chest and
skin were then closed using a silk 6–0 suture (Ethicon). Sham-operated animals
underwent the same procedure but the LAD was not ligated. Mice were administered buprenorphine (0.1 mg per kg) analgesia upon awakening, and again at 8
and 24 h postoperatively. Mice were randomized to either drug treatment or vehicle
control, as described below.
Evans blue and TTC staining. Following reperfusion, mice were anaesthetized,
intubated, and ventilated as described above. For infarct size quantiﬁcation, the
suture was left in the heart during mI/R surgery to allow the ligature to be re-tied at
the same site for infarct size assessment. A 1% Evans Blue solution was infused
through the inferior vena cava to visualize the ischemic myocardium. The heart
was removed, rinsed in 0.9% saline, and sectioned into 1 -mm slices using a heart
matrix (Zivic Instruments). Slices were incubated in 1% TTC solution for 10 min,
transferred to 10% neutral buffered formalin for 90 min, and photographed. Infarct
area and area at risk (AAR) as a percentage of left ventricle (LV) were determined
as described previously10,43. Brieﬂy, infarct area and area at risk (AAR) as a percentage of left ventricle were determined using Adobe Photoshop CS4. Samples
were normalized to each slice weight with the formula: weight (total AAR) =
[weight (slice 1) × % AAR (slice 1)] + [weight (slice 2) × % AAR (slice 2)] +
[weight (slice n) × % AAR (slice n)]. Infarct area was calculated in a similar
manner. Absolute infarct size was calculated as a ratio of weight (total infarct area)/
weight (total AAR).
SR9009 treatment. The REV-ERB agonist SR9009 treatment was given in a
blinded manner, intraperitoneally (i.p.) at a dose of 100 mg per kg in 15% cremophor, versus vehicle (15% cremophor), to mice after mI/R. The ﬁrst treatment
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was given at ZT06 following reperfusion, then once daily for 5 days, and then all
animals were maintained without any treatments for up to 8 weeks after mI/R.
Dosage was based on murine studies of in vivo efﬁcacy13,14,45,50. In a separate study
investigating only normal healthy hearts, mice were injected i.p. at ZT06 once
per day for 2 weeks. A separate cohort of mice used to investigate the time-of-day
effects of SR9009 treatment post-mI/R were given the drug at ZT18 at reperfusion
and then for all 5 days, or ZT18 post-reperfusion followed by ZT06 once daily for
5 days. Another experiment investigated whether treatment was effective if given at
ZT06 for 1, 3, or 5 days.
Echocardiography. To assess cardiac function and morphometry, animals were
assessed at baseline, 1, 4, and 8 weeks post-mI/R, in a blinded manner under light
anesthesia (1.5% isoﬂurane) using a GE Vivid 7 Dimension ultrasound machine
(GE Medical Systems) with a i13L14 MHz linear-array transducer. Measurements
were taken at the mid-papillary level and used to determine left ventricular internal
dimension at end-diastole (LVIDd), left ventricular internal dimension in systole
(LVIDs), % ejection fraction (% EF), % fractional shortening (% FS), and heart rate
(HR). A minimum of ﬁve images per mouse heart were analyzed.
Pressure–volume hemodynamics in vivo. Hemodynamics measurements were
collected at 8 weeks post surgery. Animals were anesthetised using 4% isoﬂurane,
intubated, and hemodynamic measurements were taken as previously
described10,14,51–53. Body temperature was continuously monitored and maintained. The carotid artery was isolated, a small incision was made, and a 1.2Fr
pressure volume catheter (Transonic) was advanced into the LV via the ascending
aorta. Physiologic LV and aortic pressure measurements were recorded on an
ADInstrument PowerLab. Left ventricular end systolic pressure (LVESP), diastolic
pressure (LVEDP), systolic volume (LVESV), diastolic volume (LVEDV), stroke
volume (SV), cardiac output (CO), maximum and minimum ﬁrst derivatives of LV
pressure (dP/dtmax; dP/dtmin), systolic/diastolic blood pressures (SBP/DBP) were
recorded. Mean arterial blood pressure (MAP) was calculated as DBP + (SBPDBP)/3. Continuously recorded pressures were analyzed with Lab Chart 7 (Colorado Creeks, USA).
Histology. At 8 weeks post-mI/R, mice were euthanized with isoﬂurane and cervical dislocation. Body weight (BW), heart weight (HW), and tibia length (TL) were
collected for each animal. Hearts were perfused with 1 M KCl, ﬁxed in 10% neutral
buffered formalin for 24 h, and parafﬁn embedded. Hearts were sectioned (5 μm)
from apex to base, collecting ten sections every 300 μm. Sections were stained with
Masson’s trichrome for infarct quantiﬁcation. Infarct volume was calculated as a
percentage of LV volume. Relative infarct expansion was determined by dividing
the sum of the endocardial and epicardial circumference occupied by the infarct by
the sum of the total LV epicardial and endocardial circumferences. N = 5 hearts/
group, with images taken by using Q-Capture (QImaging; Surrey, BC) and analyzed in Image J 1.46 (NIH).
RNA isolation and RT-PCR. Total RNA was isolated from hearts using TRIzol
(Invitrogen) according to the manufacturer’s instructions, and quality assessed by
Nanodrop (Thermo Scientiﬁc). RT-PCR was performed on a VIIA7 real-time PCR
system (Life Technologies) using the RNA-to-Ct one step PCR kit (ThermoFisher
Scientiﬁc) under the following protocol: reverse transcription, 48 °C for 30 min, 95
°C for 10 min for one cycle, followed by ampliﬁcation at 95 °C for 15 s, 60 °C for 1
min for 40 cycles, followed by hold at room temperature. The primers for nuclear
receptor subfamily 1, group D1 (Rev-Erbα), nuclear receptor subfamily 1, group D2
(Rev-Erbβ), circadian locomotor output cycles protein kaput (Clock), interleukin 6
(Il-6), chemokine (C-C motif) ligand 2 (Ccl2)/macrophage chemotactic protein 1
(Mcp1), Ccl7, NLR Family Pyrin Domain 3 (Nlrp3), Il-1β, Il-18, and histone are
listed in Supplementary Table 7. RT-PCR was normalized to histone using the
ΔΔCT method, as described previously10,43,54,55.
Myeloperoxidase (MPO) assay. A separate set of hearts were collected at 1, 2,
and 3 days post-mI/R for assessment of myeloid cell inﬁltration of the infarcted
myocardium, by MPO assay, as previously described10. Brieﬂy, animals were killed
by isoﬂurane and cervical dislocation, and hearts were rinsed in phosphate buffered
saline, weighed, and stored at −80 °C until use. MPO was isolated using the
EnzChek Myeloperoxidase Activity Assay Kit (Life Technologies; Molecular
Probes). Tissue was homogenized in 1 mL of 50 mM potassium phosphate buffer
(pH 6.0) with 0.5% (w/v) hexadecyltrimethyl ammonium bromide. The homogenate was sonicated and freeze-thawed three times, then centrifuged (20,000 rpm,
15 min) using a Beckman Ultracentrifuge (LE-80K). The supernatant containing
MPO was collected and quantiﬁed. Values were normalized to tissue weight. n = 5
hearts/group, and all samples were run in duplicate.
Cell tracking. Cell tracking experiments were performed as previously described23.
Brieﬂy, 0.5 μm of ﬂuoresbrite microspheres (Polysciences) were opsonized with
50% mouse serum:PBS, and injected into the infarct border zone in the LV anterior
free wall during mI/R or sham surgery. The myocardium, peripheral lymph nodes
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(mediastinal, axillary, cervical, and inguinal), spleen, and bone marrow were collected 24 h later and analyzed by ﬂow cytometry.
Immune cell quantiﬁcation by ﬂow cytometry. A separate set of hearts was
collected to quantify immune cell recruitment to the infarcted myocardium postmI/R. Brieﬂy, animals were killed as described above. Hearts were exposed, perfused via cardiac puncture with 100 units heparin in 5 mL saline, and then removed
and rinsed in saline. Epicardial fat, atria, and the free wall of the right ventricle
were removed, and the left ventricle was minced into 1–2 mm pieces with a razor
blade. Hearts were digested for 60 min at 37 °C with collagenase type II (1 mg per
mL; Worthington Biochemical Corporation) and DNase I (60 U per mL; Roche
Diagnostics Corporation) in 10 mL RPMI 1640 media (Life Technologies).
Released cells were separated using a 70-μm cell strainer (Fisher Scientiﬁc). Cell
count and viability (> 90%) were determined using the trypan blue exclusion
method. Aliquots were diluted to 1 × 106 cells in 50 μl staining buffer (PBS, 2%
BSA) and incubated with anti-CD16/32 (clone 93, eBioscience) for 5 min at 4 °C to
block Fcγ receptors. After blocking, cell suspensions were incubated with
ﬂuorochrome-conjugated antibodies in 50 μl of staining buffer in the dark for 30
min at 4 °C. To examine immunocyte recruitment cells were stained for total
leukocytes with anti-CD45-APC (clone 30-F11, eBioscience), or for macrophages
with anti-CD11b-PE (clone M1/70, Biolegend) and anti-F4/80-FITC (clone BM8,
Biolegend) and anti-CD206-AlexaFluor647 (clone C068C2, Biolegend; M1 = 206-,
M2 = 206+), or for T cells with anti-CD3e-FITC (clone 145-2C11, Biolegend) and
anti-CD4-PE (clone GK1.5, Biolegend), or anti-Ki67-APC (clone 16A8, Biolegend).
Samples were analyzed on an Accuri C6 Flow Cytometer (BD Biosciences) using
BD Accuri C6 Software (BD Biosciences) and FlowJo software (Tree Star). N = 5
hearts/group.
Irradiation and bone marrow transplantation (BMT). Experiments were performed using established protocols56. Brieﬂy, the recipient mice (WT CD45.1+,
8 weeks old) were lethally irradiated with a total dose of 9 Gy (1 Gy per min dose
rate; Clinac iX linear accelerator, Varian Medical Systems) and the following day
injected with 6–10 × 106 bone marrow cells from donor mice (WT CD45.2+, or
Nr1d1−/− CD45.2+) through the tail vein. The donor cells had been freshly harvested from mice killed by isoﬂurane and cervical dislocation, by ﬂushing femurs
and tibiae with PBS. Irradiated and reconstituted mice were housed in a strict
barrier environment in autoclaved microisolator cages. Immune cell reconstitution
of recipient mice was validated as > 96% by ﬂow cytometry at 8 weeks postBMT using anti-mouse CD45.1 (APC, clone A20, Biolegend) and anti-mouse
CD45.2 (PE, clone 104; Biolegend). Using this protocol, we produced two
types of BMT mice: WT to WT (BMTWT→WT) mice and Nr1d1−/− to WT
(BMTNr1d1−/−→WT) mice.
Cardiac myocyte and ﬁbroblast cultures. Neonatal mouse cardiomyocytes and
ﬁbroblasts were cultured using standard techniques14. Cells were plated at a density of
500 cells per mm2 in the Dulbecco’s Modiﬁed Eagles Medium/F12 (DMEM; ThermoFisher Scientiﬁc) with 10% fetal bovine serum (FBS; ThermoFisher Scientiﬁc),
0.1% bromodeoxyuridine (BrdU; Sigma). After 24 h, the cardiomyocyte cultures were
changed to serum-free DMEM containing 1% transferrin (Sigma), insulin (Sigma)
and BrdU, and SR9009 (dissolved in dimethyl sulfoxide, DMSO; Sigma) at 0 µM,
2.5 µM, 5 µM, or 10 µM. Plates were incubated under normal (5% CO2/95% Air) or
hypoxic (5% CO2/95% N2) conditions at 37 °C for 4 h and then under normoxia
conditions at 37 °C for 18 h. Cardiomyocyte cultures were assessed for cell viability by
lactate dehydrogenase assay (Cytotoxicity Detection Kit Plus, Roche), as per the
manufacturer’s directions. For the neonatal ﬁbroblast cultures, cells were plated for
24 h and then changed to media containing 100 ng per mL LPS+/– SR9009, or vehicle
controls for 24 h. Supernatant was collected for ELISAs, and cells were collected into
CellLytic MT Cell Lysis Reagent (Sigma) for western blots. Adult mouse cardiac
ﬁbroblasts were cultured in 60 -mm dishes by the method of Wang et al.57 for 24 h,
and then treated with LPS+/– SR9009 as described above, and cells were collected
into 700 µl of TRIzol (Invitrogen) for RNA isolation and RT-PCR of Nlrp3, Il-1β,
and Il-18.
Western blots. Protein lysates were prepared using CelLytic MT Cell Lysis
Reagent (Sigma) as described previously14, then subjected to SDS-PAGE, with the
Precision Plus Protein Dual Color Standard marker (Bio-Rad) and transferred to
PVDF membrane (Bio-Rad). Primary antibodies used were REV-ERBα (mouse
monoclonal, clone 4F6; 1:1000; Abgent), or REV-ERBβ (mouse monoclonal, clone
D-8; 1:1000; Santa Cruz Biotechnology), or NLRP3 (mouse monoclonal, clone
Cryo-2; 1:1000; Adipogen), or IL-1β (rabbit polyclonal, GTX74034; 1:1000; GeneTex), and incubated overnight at 4 °C. β-actin (mouse monoclonal, clone C4;
1:10,000; Millipore) was used as a loading control. Membranes were washed with
tris-buffered saline with 0.1% Tween-20 (TBS-T), and incubated for 1 h at room
temperature with horseradish peroxidase-conjugated secondary antibodies (antimouse, 7076S, 1:5000; anti-rabbit, 7074S, 1:5000; Cell Signaling) in 3% skim milk in
TBS-T. Proteins were visualized using Clarity Western ECL substrate (Bio-Rad),
according to the manufacturer’s speciﬁcations. Densitometry quantiﬁcation was
performed using Image J 1.46 (NIH). All original blots are provided in Supplementary Fig. 5.
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ELISAs. Heart protein lysates or cardiac cell culture supernatants were assayed for
IL-1β (BMS6002, Invitrogen) or IL-18 (BMS618/3, Invitrogen), according to the
manufacturer’s instructions.
Statistics and reproducibility. Values are expressed as mean ± SEM. Statistical
comparisons were done using an unpaired two-sided Student’s t test or a one-way
or two-way analysis of variance (ANOVA) followed by Tukey post hoc for multiple
comparisons, as applicable. Values of p ≤ 0.05 are considered statistically signiﬁcant. All endpoints assessed and n-values and statistics are provided in detail in
the Figure legends. All graphs are plotted as standard deviation to show the spread
and variability of the data, or standard error with individual data points for
comparing the differences between means.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

Data availability
The data that support the ﬁndings of this study are available in the Supplementary
Information, or from the corresponding author on reasonable request. The source data
underlying the main ﬁgures are shown in Supplementary Data 1.
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